Abstract:Background A number of clinical trials evaluated the efficacy and adverse effects of oral propranolol in the treatment of infantile hemangioma (IH), but the treatment has not yet been standardized. This meta-analysis aims to reevaluate the efficacy and adverse effects of oral propranolol in comparative studies and to provide a reliable basis for clinical administration in the therapy for IH. Methods Data were obtained from PubMed, Embase, Cochrane Library, Web of Science, China National Knowledge Infrastructure and Wanfang database, from inception to December 1st, 2018. The pooled risk ratios (RR) with 95% confidence intervals (95% CI) were calculated and used to evaluate the effect size. The meta-analysis was performed using the random-effects model due to heterogeneity between the studies. The Cochrane Collaboration 6 aspects of bias, methodological index for non-randomized studies and the Newcastle–Ottawa Scale were used to assess the risk for bias. Sensitivity analysis, publication bias and subgroup analysis were performed. Results Eighteen unique studies involving 2701 unique children were included in the analysis. The response rate was reported in 18 trials, which compared oral propranolol with other treatments. The heterogeneity was statistically significant ( P < 0.00001, I 2 = 95%). The difference in the response rate was statistically significant (RR = 1.40, 95% CI 1.13–1.75) while compared with the controls. However, no significant difference in the adverse events rate (RR = 0.78, 95% CI 0.45–1.34) and relapse rate (RR = 1.45, 95% CI 0.66–3.16) were found. Otherwise, the subgroup analysis indicated that the RR was 1.64 (95% CI 0.24–11.36) for low-dose propranolol (1 mg/kg/day), 1.42 (95% CI 1.12–1.80) for medium dose (2 mg/kg/day) and 1.46 (95% CI 1.17–1.82) for high dose (3 mg/kg/day), but the high dose had higher adverse events rate than medium dose, with 3.60% and 86.22%, respectively. The effectiveness of propranolol therapy among cases of treatment duration less than 6 months (RR = 1.24, 95% CI 1.05–1.47) was inferior to that of treatment duration greater than or equal to 6 months (RR = 1.46, 95% CI 1.11–1.92). Conclusions This meta-analysis reveals that oral propranolol is superior to other treatments in improving response rate of IH and can be used as the first-line therapy for IH children. A dosage of 2 mg/kg/day propranolol orally may be a good choice for IH. However, further studies are essential.

Concurrent versus sequential combination of propranolol and dual-wavelength laser ( 585 nm and 1064 nm ) to treat complicated infantile hemangiomas

Oral propranolol combined with topical timolol for compound infantile hemangiomas: a retrospective study

Combination therapy of oral propranolol and combined Nd:YAG/pulsed dye laser therapy in infantile hemangiomas: a retrospective analysis of 48 treated hemangiomas in 30 children

Efficacy and adverse effects of oral propranolol in infantile hemangioma: a meta-analysis of comparative studies

Additive effect of propranolol and pulsed dye laser for infantile hemangioma

The Efficacy and Safety of Treatments for Infantile Hemangiomas: a Bayesian Network Meta‐analysis

The efficacy and safety of treatments for infantile hemangiomas: a Bayesian network meta-analysis

Comparison of the efficacy and safety of lasers, topical timolol, and combination therapy for the treatment of infantile hemangioma: a meta‐analysis of 10 studies

Comparison of efficacy and safety between oral propranolol combined with and without intralesional injection of lauromacrogol for infantile hemangioma

Evaluation of a New Q-switched Nd:YAG Laser on Premacular Hemorrhage.

Propranolol for infantile hepatic hemangioendothelioma: Clinical evaluation of drug efficacy and safety using a single-center patient cohort

Efficacy and Safety of Oral Propranolol or Topical Timolol for the Treatment of Superficial Infantile Hemangiomas

Left ventricular thrombosis after anterior myocardial infarction with and without thrombolytic treatment

Algorithm-based Management of Infantile Hemangiomas: Reducing Sequelae and Surgical Interventions

Diffuse infantile hepatic hemangioma successfully treated with propranolol orally: a case report and literature review

Safety assessment of propranolol for infantile hemangioma: a study in an Asian population

Exploration of the optimal time to discontinue propranolol treatment in infantile hemangiomas: A prospective study

Propranolol for the treatment of infantile hemangiomas: a nine-year monocentric experience from a tertiary hospital

Oral propranolol for the treatment of hemangiomas in high-risk infants: safety and cost analysis of outpatient-initiated therapy

Effectiveness of Propranolol in the Treatment of Infantile Hemangioma Beyond the Proliferation Phase

Oral atenolol treatment for infantile hemangiomas: clinical analysis of 133 consecutive patients